Overview

* Precigen ( PGEN ) Q3 net loss widens significantly due to non-cash items like warrant liabilities

* PAPZIMEOS receives FDA approval, launches as first treatment for adults with RRP

* Company advances PAPZIMEOS commercialization with over 90% target institutions engaged

* Cash, cash equivalents, and investments totaled $123.6 million as of September 30, 2025

Outlook

* Company expects current cash position to fund operations to cash flow break-even

* Precigen ( PGEN ) submitted MAA to European Medicines Agency for PAPZIMEOS

* Company advancing payer and formulary access for PAPZIMEOS

Result Drivers

* INCREASED R&D EXPENSES: Research and development expenses increased by $1.0 million, or 9%, compared to the three months ended September 30, 2024

*

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$146.34

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Precigen Inc ( PGEN ) is $8.25, about 51.3% above its November 12 closing price of $4.02

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)